Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy

Area of Science:

• Biochemistry
• Genetics
• Molecular Biology

Background:

• Duchenne muscular dystrophy (DMD) is a severe genetic disorder caused by mutations in the DMD gene, leading to progressive muscle degeneration and premature death.
• The absence of functional dystrophin protein results in profound muscle weakness and eventual heart and respiratory failure.
• Antisense oligonucleotides (AONs) represent a promising therapeutic strategy for DMD by targeting pre-mRNA splicing.

Purpose of the Study:

• To review recent advancements in clinical trials utilizing AONs for DMD treatment.
• To discuss the current challenges and future directions for AON-based therapies in DMD.

Main Methods:

• Review of clinical trial data and scientific literature on AONs for DMD.
• Analysis of AON mechanisms, including pre-mRNA splicing modulation and exon skipping.
• Evaluation of AON delivery methods (local and systemic) and their safety profiles.

Main Results:

• Clinical trials demonstrate that AONs can restore partially functional dystrophin protein in DMD patients.
• Acceptable safety profiles have been observed with both local and systemic AON delivery.
• Significant progress has been made in restoring dystrophin expression and function.

Conclusions:

• AONs are a viable therapeutic approach for Duchenne muscular dystrophy, with demonstrated potential to restore dystrophin protein.
• Further research is essential to enhance AON delivery efficiency and broaden treatment applicability to more DMD patients.
• Addressing challenges in efficacy and developing diverse AONs are critical for realizing the full therapeutic potential of this approach.